Compounds > hql-79
Page last updated: 2024-12-11

hql-79

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6540277
CHEMBL ID574003
SCHEMBL ID347141
SCHEMBL ID21496196
MeSH IDM0299103

Synonyms (43)

Synonym
162641-16-9
CC-704 ,
hql ,
4-(benzhydryloxy)-1-[3-(1h-tetraazol-5-yl)propyl]piperidine
hql-79 ,
2CVD ,
DB07917
CHEMBL574003 ,
1-(3-(2h-tetrazol-5-yl)propyl)-4-(benzhydryloxy)piperidine
1-(3-(1h-tetrazol-5-yl)propyl)-4-(benzhydryloxy)piperidine
bdbm50300128
4-benzhydryloxy-1-[3-(2h-tetrazol-5-yl)propyl]piperidine
FT-0643573
AM84555
gtpl6662
4-[di(phenyl)methoxy]-1-[3-(2h-tetrazol-5-yl)propyl]piperidine
hql79
SCHEMBL347141
hql 79
4-(diphenylmethoxy)-1-(3-2h-tetrazol-5-yl)propyl]-piperidine
DTXSID50424898
TZQGXAHOROZEKN-UHFFFAOYSA-N ,
4-(diphenylmethoxy)-1-[3-(1h-tetrazol-5-yl)propylpiperidine
AKOS024457666
HMS3648E13
EX-A091
J-009960
4-(diphenylmethoxy)-1-[3-(2h-tetrazol-5-yl)propyl]piperidine
NCGC00343938-06
hql-97
4-(diphenylmethoxy)-1-[3-(1h-tetrazol-5-yl)propyl]piperidine
SCHEMBL21496196
AKOS032947265
BCP06026
F17406
Q27077992
AS-16439
SR-01000946205-1
sr-01000946205
HY-108259
CS-0027831
piperidine, 4-(diphenylmethoxy)-1-[3-(2h-tetrazol-5-yl)propyl]-
AC-36790

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 2D6Homo sapiens (human)Potency6.00810.00108.379861.1304AID1645840
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hematopoietic prostaglandin D synthaseHomo sapiens (human)IC50 (µMol)26.50000.07100.92223.8000AID442514; AID499186; AID499201
Hematopoietic prostaglandin D synthaseHomo sapiens (human)Ki5.00005.00005.00005.0000AID1719064
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Glutathione-requiring prostaglandin D synthaseHomo sapiens (human)Kd0.80000.80000.80000.8000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
prostaglandin biosynthetic processHematopoietic prostaglandin D synthaseHomo sapiens (human)
prostaglandin metabolic processHematopoietic prostaglandin D synthaseHomo sapiens (human)
signal transductionHematopoietic prostaglandin D synthaseHomo sapiens (human)
locomotory behaviorHematopoietic prostaglandin D synthaseHomo sapiens (human)
negative regulation of male germ cell proliferationHematopoietic prostaglandin D synthaseHomo sapiens (human)
glutathione metabolic processHematopoietic prostaglandin D synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
magnesium ion bindingHematopoietic prostaglandin D synthaseHomo sapiens (human)
glutathione transferase activityHematopoietic prostaglandin D synthaseHomo sapiens (human)
prostaglandin-D synthase activityHematopoietic prostaglandin D synthaseHomo sapiens (human)
calcium ion bindingHematopoietic prostaglandin D synthaseHomo sapiens (human)
protein bindingHematopoietic prostaglandin D synthaseHomo sapiens (human)
protein homodimerization activityHematopoietic prostaglandin D synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nucleoplasmHematopoietic prostaglandin D synthaseHomo sapiens (human)
cytoplasmHematopoietic prostaglandin D synthaseHomo sapiens (human)
cytosolHematopoietic prostaglandin D synthaseHomo sapiens (human)
intracellular membrane-bounded organelleHematopoietic prostaglandin D synthaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID499198Cytotoxicity against human MEG-01S cells assessed as reduction in cell viability after 24 hrs by MTT assay2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Development and characterization of new inhibitors of the human and mouse hematopoietic prostaglandin D(2) synthases.
AID499186Inhibition of human H-PGDS expressed in Escherichia coli BL21 DE2 by enzyme immuno assay2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Development and characterization of new inhibitors of the human and mouse hematopoietic prostaglandin D(2) synthases.
AID499201Inhibition of human H-PGDS expressed in Escherichia coli BL21 DE2 by enzyme immuno assay at 50 uM2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Development and characterization of new inhibitors of the human and mouse hematopoietic prostaglandin D(2) synthases.
AID499192Inhibition of H-PGDH in mouse BMDM cells assessed as inhibition of LPS-stimulated TXB2 production after 24 hrs by EIA2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Development and characterization of new inhibitors of the human and mouse hematopoietic prostaglandin D(2) synthases.
AID1719064Competitive inhibition of human HPGDS using PGH2 as substrate
AID499191Inhibition of H-PGDH in mouse BMDM cells assessed as inhibition of LPS-stimulated 6Keto PGF1alpha production after 24 hrs by EIA2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Development and characterization of new inhibitors of the human and mouse hematopoietic prostaglandin D(2) synthases.
AID499190Inhibition of H-PGDH in mouse BMDM cells assessed as inhibition of LPS-stimulated PGE2 production after 24 hrs by EIA2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Development and characterization of new inhibitors of the human and mouse hematopoietic prostaglandin D(2) synthases.
AID442514Inhibition of human H-PGDS expressed in Escherichia coli BL21 assessed as rate of glutathione-chloro-dinitro benzene conjugation2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Identification and characterisation of new inhibitors for the human hematopoietic prostaglandin D2 synthase.
AID499197Inhibition of H-PGDH in human MEG-01S cells assessed as inhibition of A-23187-stimulated PGD2 production at 100 uM after 24 hrs by EIA2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Development and characterization of new inhibitors of the human and mouse hematopoietic prostaglandin D(2) synthases.
AID499189Cytotoxicity against mouse BMDM cells assessed as reduction in cell viability at 100 uM after 24 hrs by MTT assay2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Development and characterization of new inhibitors of the human and mouse hematopoietic prostaglandin D(2) synthases.
AID442515Inhibition of human H-PGDS expressed in Escherichia coli BL21 assessed as rate of glutathione-chloro-dinitro benzene conjugation at 50 uM2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Identification and characterisation of new inhibitors for the human hematopoietic prostaglandin D2 synthase.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1345296Human H-PGDS (Prostaglandin synthases)2006The Journal of biological chemistry, Jun-02, Volume: 281, Issue:22
Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2006The Journal of biological chemistry, Jun-02, Volume: 281, Issue:22
Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase.
AID1811Experimentally measured binding affinity data derived from PDB2006The Journal of biological chemistry, Jun-02, Volume: 281, Issue:22
Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's3 (42.86)24.3611
2020's3 (42.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.61 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
diclofenac
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.		2.0510amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
ethacrynic acid
Ethacrynic Acid: A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.. etacrynic acid : An aromatic ether that is phenoxyacetic acid in which the phenyl ring is substituted by chlorines at positions 2 and 3, and by a 2-methylidenebutanoyl group at position 4. It is a loop diuretic used to treat high blood pressure resulting from diseases such as congestive heart failure, liver failure, and kidney failure. It is also a glutathione S-transferase (EC 2.5.1.18) inhibitor.		2.0510aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid		EC 2.5.1.18 (glutathione transferase) inhibitor;
ion transport inhibitor;
loop diuretic
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		2.4620aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
nocodazole
[no description available]		2.0510aromatic ketone;
benzimidazoles;
carbamate ester;
thiophenes		antimitotic;
antineoplastic agent;
microtubule-destabilising agent;
tubulin modulator
sulfasalazine
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.		2.0510
sulfobromophthalein
Sulfobromophthalein: A phenolphthalein that is used as a diagnostic aid in hepatic function determination.		2.05102-benzofurans;
organobromine compound;
organosulfonic acid;
phenols		dye
zomepirac
zomepirac: RN given refers to parent cpd; structure		2.0510aromatic ketone;
monocarboxylic acid;
monochlorobenzenes;
pyrroles		cardiovascular drug;
non-steroidal anti-inflammatory drug
ticrynafen
Ticrynafen: A novel diuretic with uricosuric action. It has been proposed as an antihypertensive agent.. tienilic acid : An aromatic ketone that is 2,3-dichlorophenoxyacetic acid in which the hydrogen at position 4 on the benzene ring is replaced by a thiophenecarbonyl group. A loop diuretic used to treat hypertension, it was withdrawn from the market in 1982 due to links with hepatitis.		2.0510aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid;
thiophenes		antihypertensive agent;
hepatotoxic agent;
loop diuretic
oxfendazole
[no description available]		2.0510benzimidazoles;
carbamate ester;
sulfoxide		antinematodal drug
ramatroban
[no description available]		2.0510organic molecular entity
ml-3000
[no description available]		2.0510
ConditionIndicatedRelationship StrengthStudiesTrials
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510